CHE vs UNH

Chemed Corporation exhibits a stark divergence between its fundamental valuation and current market price, trading at a massive premium to its Graham Number ($171.6) and Intrinsic Value ($128.24). While the company maintains a stable Piotroski F-Score of 4/9 and an exceptionally low Debt/Equity ratio of 0.15, these health metrics are offset by negative YoY revenue and earnings growth. The combination of declining profitability, bearish insider activity from the CEO, and a valuation that is nearly 2.5x its defensive fair value suggests significant downside risk.

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.